---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-26-006773"
form_type: "8-K"
ticker: "NTHI"
cik: "0001979414"
company_name: "NEONC TECHNOLOGIES HOLDINGS, INC."
filed_at: "2026-06-23T21:00:27+00:00"
generated_at: "2026-06-23T21:02:31.527323+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NeOnc receives UAE IND approval for NEO100; Phase 2a data expected by end of July 2026

## Summary
- UAE DOH granted IND status for NEO100 across adult Phase 1-2 and pediatric studies for recurrent gliomas.
- NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations.
- Top-line Phase 2a data from fully enrolled NEO100-01 trial expected by end of July 2026.
- Authorization follows recent UAE IND clearance for NEO212, expanding development footprint.

## SEC filing metadata
- accession: 0001829126-26-006773
- form_type: 8-K
- ticker: NTHI
- cik: 0001979414
- company_name: NEONC TECHNOLOGIES HOLDINGS, INC.
- filed_at: 2026-06-23T21:00:27+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1979414/000182912626006773/0001829126-26-006773-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1979414/000182912626006773/neonctechnologies_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-26-006773
- JSON: https://secwatch.observer/filing/0001829126-26-006773.json
- Plain text: https://secwatch.observer/filing/0001829126-26-006773.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.